Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts

Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options

(2013) Kathryn A Culos et al.   ANNALS OF PHARMACOTHERAPY

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Tumor Initiation in Human Malignant Melanoma and Potential Cancer Therapies

(2012) Jie Ma et al.   Anti-Cancer Agents in Medicinal Chemistry

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Melanoma: from mutations to medicine

(2012) H. Tsao et al.   GENES & DEVELOPMENT

CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

(2012) Yan Lin et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Current management and novel agents for malignant melanoma

(2012) Byung Lee et al.   Journal of Hematology & Oncology

Melanoma: New Insights and New Therapies

(2012) Vasiliki A. Nikolaou et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

A new paradigm tumor for drug development

(2012) Alexander M. M. Eggermont et al.   Nature Reviews Clinical Oncology

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential

(2012) Giovanni Sette et al.   PLoS One

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

(2012) Muhammad Khattak et al.   Therapeutic Advances in Medical Oncology

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

(2011) Peter D. Boasberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth

(2011) G. Civenni et al.   CANCER RESEARCH

From Cancer Stem Cells to Tumor Maintenance in Melanoma

(2011) Mizuho Fukunaga-Kalabis et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2

(2011) S. Rizzo et al.   MOLECULAR CANCER THERAPEUTICS

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion

(2011) D. Iliopoulos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized

(2010) Elsa Quintana et al.   CANCER CELL

Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell

(2010) M. A. Held et al.   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

The therapeutic promise of the cancer stem cell concept

(2010) Natasha Y. Frank et al.   JOURNAL OF CLINICAL INVESTIGATION

In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression

(2010) Rong-Yi Chen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

(2010) Christophe Frémin et al.   Journal of Hematology & Oncology

Selection of Tumorigenic Melanoma Cells Using ALDH

(2010) Jim B. Boonyaratanakornkit et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells

(2010) Michela Perego et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

(2010) Alexander D. Boiko et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma

(2010) Lina Prasmickaite et al.   PLoS One

Identification and targeting of cancer stem cells

(2009) Tobias Schatton et al.   BIOESSAYS

Melanoma-initiating cells: a compass needed

(2009) Yosef Refaeli et al.   EMBO REPORTS

Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape

(2009) Aleksandar Sekulic et al.   MAYO CLINIC PROCEEDINGS

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

(2009) G. Bertolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy

(2008) Keiran S.M. Smalley et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE

Efficient tumour formation by single human melanoma cells

(2008) Elsa Quintana et al.   NATURE